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Abstract 
Objective: Topoisomerase 1 (topo-1) is an important target 
for the treatment of metastatic colorectal cancer (CRC). The 
aim of the present study was to evaluate the correlation be- 
tween topo-1 single-nucleotide polymorphisms (SNPs) and 
clinical outcome in metastatic CRC (mCRC) patients. Meth- 
ods: With the use of specific software (PROMO 3.0), we per- 
formed an in silico analysis of topo-1 promoter SNPs; the 
rs6072249 and rs34282819 SNPs were included in the study. 
DNA was extracted from 105 mCRC patients treated with 
FOLFIRI ± bevacizumab in the first line. SNP genotyping was 
performed by real-time PCR. Genotypes were correlated 
with clinical parameters (objective response rate, progres- 
sion-free survival, and overall survival). Results: No single 
genotype was significantly associated with clinical variables. 
The G allelic variant of rs6072249 topo-1 SNP is responsible 
for GC factor and X-box-binding protein transcription factor 
binding. The same allelic variant showed a nonsignificant 
trend toward a shorter progression-free survival (GG, 7.5 
months; other genotypes, 9.3 months; HR 1.823, 95% CI 
0.8904–3.734; p = 0.1). Conclusion: Further analyses are 
needed to confirm that the topo-1 SNP rs6072249 and tran- 
scription factor interaction could be a part of tools to predict 
clinical outcome in mCRC patients treated with irinotecan- 
based regimens. © 2016 S. Karger AG, Basel 
 
 
 
Introduction 
 
Colorectal cancer (CRC) is one of the most common 
causes of death by cancer in Western countries [1]. De- 
spite recent advances, the prognosis remains poor for 
metastatic CRC (mCRC) patients, with a median overall 
survival (OS) of approximately 30 months in most recent 
studies [1]. Combination chemotherapy with a fluoropy- 
rimidine [5-fluorouracil (5-FU) or capecitabine] and ox- 
aliplatin (LOHP) or irinotecan (CPT-11) is the mainstay 
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of treatment for mCRC patients. Combining chemother- 
apy with the anti-vascular endothelial growth factor 
(VEGF) antibody bevacizumab may further improve out- 
come in the advanced disease setting [2]. Clinical trials 
conducted on mCRC patients demonstrated higher activ- 
ity and efficacy for LOHP- or CPT-11-based doublets 
with biologics, with response rates (RRs) around 40–50% 
and a median OS around 24 months [3]. 
Topoisomerase 1 (topo-1) is the specific target of CPT- 
11. CPT-11 is a pro-drug that is converted by hydrolysis 
to SN-38 (active metabolite) by carboxylesterases. SN- 
38 is inactivated through glucuronidation by uridine di- 
phosphate-glucuronosyltransferase. CPT-11 binds the 
‘DNA-topo-1 cleavage complex’, leading to irreversible 
DNA damage and cell death [4]. Some studies showed a 
correlation between DNA topo-1 activity and sensitivity 
to CPT-11 [5]. It is well known that topo-1 gene copy 
number may be correlated with the sensitivity to CPT- 
11 [6] and that a low level of topo-1 expression is associ- 
ated with the development of resistance to CPT-11 [7]. 
Epigenetic regulation of topo-1 promoter is crucial for 
determining transcription factor binding (TFB), gene 
expression, and CPT-11 sensitivity in CRC cells [8]. 
However, most mCRC patients did not achieve an ob- 
jective response [9]. Moreover, CPT-11 efficacy is bur- 
dened by a potentially severe toxicity. The individualiza- 
tion of cytotoxic therapy in patients with cancer (and in 
particular in mCRC, where different options are avail- 
able) is essential for the success of the therapy and the 
avoidance of futile toxicity for patients with nonsensi- 
tive disease. 
Based on the identification of molecular markers in- 
cluding KRAS, BRAF, and PI3K mutations and the ex- 
pression of topo-1, ERCC-1, and thymidylate synthase, 
the efforts of the clinicians and pharmacologists should 
be directed towards the validation of putative predictive 
biomarkers, and they should combine them so as to ob- 
tain a shared therapeutic algorithm. Indeed, research on 
personalized treatment of mCRC patients beyond the 
confirmed negative predictive role of RAS mutations for 
anti-epidermal growth factor receptor (EGFR) antibodies 
is far from conclusive [10]. 
Based on the pivotal role of topo-1 in mCRC treatment, 
we searched for topo-1 single-nucleotide polymorphisms 
(SNPs) located in the promoter region in order to analyze 
if topo-1 genetic variants may affect gene expression and, 
therefore, clinical outcome in mCRC patients treated 
with CPT-11-based regimens. Moved by this idea, we 
aimed at studying the role of two topo-1 SNPs in mCRC 
patients treated with first-line FOLFIRI ± bevacizumab. 
Materials and Methods 
Patients and Methods 
Patients with histologically confirmed metastatic colorectal ad- 
enocarcinoma receiving first-line FOLFIRI (CPT-11 180 mg/sqm 
i.v. on day 1, leucovorin 200 mg/sqm i.v. on day 1, and 5-FU 400 
mg/sqm bolus i.v. on day 1, followed by 5-FU 2,400 mg/sqm 46- 
hour continuous infusion i.v. on days 1–3 or 5-FU 3,200 mg/sqm 
48-hour continuous infusion i.v. on days 1–3) with or without bev- 
acizumab 5 mg/kg i.v. on day 1 (cycles repeated every 2 weeks) 
were enrolled in the study. Eligibility requirements included: age 
≥18 years; Eastern Cooperative Oncology Group performance sta- 
tus 0–2; life expectancy of at least 3 months, and signed informed 
consent for genetic analyses. Blood samples were anonymously 
stored at –20°C in laboratories of the Unit of Clinical Pharmacol- 
ogy and Pharmacogenetics, Department of Clinical and Experi- 
mental Medicine, University of Pisa, Pisa, Italy. 
Response evaluation was based on investigator-reported as- 
sessment by RECIST v.1.0 criteria [11]: carcinoembryonic antigen 
measurements and contrast-enhanced total-body computed to- 
mography scans were performed every 2 months until disease pro- 
gression. Progression-free survival (PFS) was considered as the in- 
terval ranging from the date of treatment start until the evidence 
of disease progression or death from any cause, whichever oc- 
curred first; OS was considered as the interval ranging from the 
date of treatment start until death from any cause. 
 
DNA Isolation 
Genomic DNA was extracted from peripheral venous blood 
samples (5 ml) from 105 mCRC patients. DNA was isolated with 
QIAamp DNA mini kit (Qiagen). The purity and the quantity of 
DNA were read at 260 and 280 nm with a NanoDrop spectropho- 
tometer (Thermo Scientific). The contamination by proteins was 
evaluated by the calculation of the 260/280 ratio. 
 
In silico Analysis 
Topo-1 SNPs were screened with specific software. We performed 
an in silico functional characterization based on missense mutations, 
TFB, and miRNA binding. PROMO 3.0 software (http://alggen.lsi. 
upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 [12, 
13]; we considered human factors and human binding sites with a 
maximum matrix dissimilarity rate of 15), GeneCard (http://www. 
genecards.org/), and MicroSNiPer (http://epicenter.ie-freiburg. 
mpg.de/services/microsniper/) [14] were employed. 
 
SNP Genotyping 
The topo-1 SNPs g.3881A>G (rs6072249) and g.5164C>A 
(rs34282819) were analyzed with real-time PCR (Applied Biosys- 
tems). The PCR reactions were done using 20 ng of genomic DNA 
diluted in 11.875 μl DNase/RNase-free water, 12.5 μl of TaqMan 
Universal Master Mix (Applied Biosystems) with AmpliTaq Gold, 
and 0.625 μl of the SNP genotyping assay mix (specific primers and 
probe) in 25 μl total volume (protocol: http://www3.appliedbiosys- 
tems.com/cms/groups/mcb_support/documents/generaldocu- 
ments/cms_042998.pdf). The allelic content of each sample in the 
plate was determined by reading the generated fluorescence. 
 
Statistical Analysis 
A χ2 test for trend was used to evaluate the association of inves- 
tigated SNPs with RRs. PFS and OS curves were obtained with the 
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Fig. 1. Hypothesis of interaction between 
the g.3881A>G topo-1 SNP and TFB lead- 
ing to a shorter PFS: patients carrying the 
g.3881G/G genotype, through GCF and 
XBP-1 binding, could express lower levels 
of topo-1 and be resistant to CPT-11. 
 
 
 
Kaplan-Meier method, and we used the log-rank test (significant 
p value <0.05 for a two-tailed test) to compare the survival distri- 
butions between the different genotypes. GraphPad Prism 6 soft- 
ware was used for statistical analyses. 
Table 1. Patient characteristics 
 
We obtained written informed consent from all patients for 
genetic polymorphism analysis. The study was approved by the 
ethical committee of the Pisa University Hospital and was carried 
out in accordance with the Code of Ethics of the World Medical 
Association (Declaration of Helsinki). 
 
 
 
Results 
 
Patients’ Characteristics 
A total of 105 patients were enrolled in the study. Pa- 
tient characteristics are listed in table 1. Overall, 50 pa- 
tients achieved an objective response (4 complete and 46 
 
disease stabilization as best response and 20 patients 
(19%) progressed during treatment. Because of the lim- 
itation of the small sample size of the bevacizumab co- 
Patients 46 46 13 
Median age (range), years 66 (49–78) 66 (45–80) 64 (80–35) 
Gender 
Male 30 28 8 
Female 16 18 5 
ECOG performance status 
0 37 34 11 
1 8 11 1 
2 1 1 0 
Involved organs 
1 21 25 9 
2 17 15 0 
≥3 8 6 4 
Previous adjuvant chemotherapy 
Yes 12 15 2 
No 34 31 11 
FOLFIRI 43 40 13 
FOLFIRI + bevacizumab 3 6 0 
ECOG = Eastern Cooperative Oncology Group. 
hort, a nonsignificant difference in RR was noted be-    
tween the FOLFIRI and the FOLFIRI plus bevacizumab 
groups (45 vs. 78%; p = 0.082). At a median follow-up of 
38.7 months, all patients experienced disease progres- 
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Fig. 2. PFS of g.3881A>G topo-1 SNP variants: G/G versus other 
genotypes. 
 
Fig. 3. OS of g.3881A>G topo-1 SNP variants: G/G versus other 
genotypes. 
 
 
Table 2. Distribution of different genotypes for studied SNPs 
 
n % 
 
Genotype for g.5164C>A 
AA 90 90 
AC 8 8 
CC 2 2 
Genotype for g.3881A>G 
 
AA 46 44 
AG 46 44 
GG 13 12 
 
 
 
 
 
sion, and 79 patients died; the median PFS and OS were 
8.8 and 21.7 months, respectively. 
 
In silico Characterization of g.3881A>G and 
g.5164C>A SNPs 
With an in silico analysis, we selected two topo-1 
SNPs that showed functional relevance in TFB change, 
and we evaluated the impact of these SNPs in 105 mCRC 
patients treated with first-line FOLFIRI ± bevacizumab. 
The selected SNPs are in Hardy-Weinberg equilibrium. 
We investigated with PROMO 3.0 whether the SNPs lo- 
cated in the topo-1 promoter may affect TFB. We select- 
ed 2 SNP variants, namely g.3881A>G and g.5164C>A. 
The g.3881A>G SNP is located on chromosome 20 in 
the 2-kb upstream variant. The g.3881G allele is respon- 
sible for GC factor (GCF) and X-box-binding protein 1 
(XBP-1) TFB (fig. 1). The g.5164A allele is responsible 
for peroxisome proliferator-activated receptor α 
(PPAR-α) and retinoid X receptor α (RXR-α) TFB 
(fig. 1). 
 
SNP Genotype Correlation with Clinical Outcome 
Prevalences of different genotypes for g.5164C>A and 
g.3881A>G are listed in table 2. We genotyped 105 mCRC 
patients for the g.3881A>G SNP and 100 mCRC patients 
for the g.5164C>A SNP. For the g.5164C>A SNP, we ex- 
cluded 5 DNA samples whose genotype was unclear. No 
significant associations were found between g.5164C>A 
and clinical parameters (RR, PFS, and OS; p > 0.05; data 
not shown). Concerning the g.3881A>G SNP, the median 
PFS of patients carrying the A/A variant (n = 46; events = 
46) was 8.9 months; for the A/G variant (n = 46; events = 
46), it was 9.7 months, and for the G/G variant (n = 13; 
events = 13), it was 7.5 months (log-rank p = 0.037). This 
trend was retained also when patients receiving bevaci- 
zumab were excluded from the analysis (the median PFS 
for A/A, A/G, and G/G patients was 8.2, 8.9, and 7.5 
months; log-rank p = 0.093). Moreover, we noticed some 
interesting, although not statistically significant, differ- 
ences between the three genotypes of g.3881A>G con- 
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100 
 
80 
G/G 
Others 
60 
 
40 
 
20 
 
0 
0 4 8 12 16 20 24 28 32 
Time (months) 
G/G   13 12 6 3 1 1 1 1 
Others   92 80 56 27 14 7 4 3 
No. at risk 
100 OS 
G/G 
Others 
50 
0 
0 10 20 30 40 50 60 70 
Time (months) 
G/G   13 12 4 
Others   92 71 47 
3 
17 
No. at risk 
3 
6 
1 
3 
1 
2 
Su
rv
iv
al
 (%
) 
Su
rv
iv
al
 (%
) 
Topo-1 Variants in mCRC Patients Oncology 
DOI: 10.1159/000448004 
5  
cerning OS. The median OS of patients carrying the A/A 
genotype (n = 46; events = 38) was 16.6 months; for the 
A/G genotype (n = 46; events = 30), it was 23.1 months, 
and for the G/G genotype (n = 13; events = 11), it was 18.7 
months (log-rank p = 0.053). Considering the gene dos- 
age effect, no single genotype was significantly associated 
with clinical variables. However, when compared to all 
other genotypes, the g.3881G/G allelic variant showed a 
nonsignificant trend with a shorter PFS (median for GG, 
7.5 months vs. for others, 9.3 months; HR 1.823, 95% CI 
0.8904–3.734; p = 0.1; fig. 2) and OS (median for GG, 18.7 
months vs. for others, 22.4 months; HR 0.8348, 95% CI 
0.3059–1.364; p = 0.7; fig. 3). As regards RR, no difference 
was noted between the three different genotypes of the 
g.3881A>G SNP (G/G vs. A/G vs. A/A: 54 vs. 50 vs. 43%; 
p = 0.73). Even after grouping the A/G and A/A geno- 
types, the G/G genotype was not associated with RR (G/G 
vs. others: 54 vs. 47%; odds ratio 1.3295, 95% CI 0.4148– 
4.2615; p = 0.769). 
 
 
Discussion 
 
Since SNP genotyping can be easily performed from 
blood samples and is more convenient to adopt in clinical 
practice, we explored the role of topo-1 SNPs in mCRC 
patients with regard to clinical outcome. Considering the 
gene dosage effect, no single genotype was significantly 
associated with clinical parameters of activity and effica- 
cy. This is consistent with a previous study on topo-1 
pharmacogenetics, where no significant relationship was 
found between the topo-1 polymorphisms studied and 
topo-1 expression, with an unidentified association with 
drug cytotoxicity [15]. In our study, these results could be 
partly due to the small sample size of the population in- 
cluded. 
Interestingly, we found that the g.3881G/G genotype 
showed a trend-like association with shorter PFS. Even 
though the lack of bevacizumab in the G/G patient cohort 
could partly explain this result, several additional consid- 
erations should be considered. Indeed, the g.3881G allele 
is located in the binding region of XBP-1 and GCF and 
could, therefore, modulate this binding. Since binding 
sites are known to interact frequently with different fac- 
tors in different contexts, it is possible that XBP-1 and 
GCF binding could trigger mechanisms related to a dif- 
ferent prognosis and response to treatment. The name 
GCF is correlated with the ability of this transcription fac- 
tor to bind to GC-rich sequences [16]. GCF is a nuclear 
phosphoprotein able to repress transcription and to de- 
crease mRNA levels of several genes including transform- 
ing growth factor-α (TGF-α), insulin-like growth factor-II 
(IGF-II), and c-met in gastric tumor cell lines and EGFR 
[17, 18]. GCF plays a critical role in the regulation of cell 
growth, even if the molecular mechanism is not com- 
pletely understood. By increasing GCF binding, the topo- 
1 g.3881G allele could contribute to topo-1 repression. 
Since GCF is able to repress transcription of topo-1 and 
CPT-11 sensitivity is correlated with topo-1 expression 
[17, 18], patients carrying the g.3881G/G genotype could 
express lower levels of topo-1 and, therefore, be resistant 
to CPT-11. This mechanism could be at the basis of the 
shorter PFS observed in mCRC patients treated with the 
FOLFIRI regimen (fig. 1). 
XBP-1 is a transcription factor identified as a basic 
region-leucine zipper that binds to the X2 box in the pro- 
moter region of several proteins regulating its expression 
[19]. XBP-1 is essential for hepatocyte growth [20] and 
for plasma differentiation [21], and it is a transcriptional 
regulator of endoplasmic reticulum stress. Recent studies 
have shown XBP-1 overexpression in breast carcinoma 
[22] and in CRC [23]. XBP-1 could play an interesting 
role in CRC, accelerating the cell growth [23] (fig. 1). In- 
terestingly, also XBP-1 was shown to repress gene ex- 
pression of target genes. XBP-1 binding of specific DNA 
sequences may lead to modulation of different genes 
[24], and its upregulation leads to cell death [25]. It is 
conceivable that XBP-1 inhibits topo-1 expression in 
CRC cells. In patients carrying at least one G allele, in- 
creased XBP-1 binding may contribute to topo-1 down- 
regulation and CPT-11 insensitivity in g.3881GG pa- 
tients [26]. Indeed, also in this case, we need further 
mechanistic studies to explain and validate the interac- 
tion of transcription factors with the topo-1 g.3881A>G 
SNP in mCRC patients. 
We are conscious that our study has several limita- 
tions. Even if we had identified a trend towards a signifi- 
cant prognostic factor for PFS, this result should be con- 
firmed in larger patient series. Moreover, investigations 
of biological mechanisms and consequences of the 
g.3881A>G SNP might contribute to supporting our 
finding. 
In conclusion, we identified a variant of the topo-1 
g.3881A>G SNP showing a trend towards an association 
with shorter PFS among mCRC patients treated with 
FOLFIRI ± bevacizumab. If these results are confirmed in 
larger series, the g.3881GG variant could be part of tools 
predicting the clinical outcome of mCRC patients treated 
with CPT-11-based therapy. 
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